Enanta Pharmaceuticals, Inc. Forecasted to Post Q1 2025 Earnings of ($1.15) Per Share (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce expects that the biotechnology company will earn ($1.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.90) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.44) EPS, Q3 2025 earnings at ($1.57) EPS and Q4 2025 earnings at ($1.66) EPS.

Other analysts have also issued reports about the company. JMP Securities cut their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. dropped their price objective on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $12.76 on Thursday. Enanta Pharmaceuticals has a 52 week low of $8.08 and a 52 week high of $28.25. The company’s 50 day moving average price is $14.88 and its two-hundred day moving average price is $12.08. The company has a market capitalization of $269.95 million, a P/E ratio of -2.04 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million for the quarter, compared to the consensus estimate of $22.74 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 417.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,281 shares during the period. Clearstead Advisors LLC acquired a new stake in Enanta Pharmaceuticals during the third quarter worth approximately $57,000. Quantbot Technologies LP increased its stake in Enanta Pharmaceuticals by 2,300.0% during the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,900 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at $113,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $118,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.